SS
KTTA icon

SBI Securities’s Pasithea Therapeutics KTTA Stock Holding History

SBI Securities’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542 Hold
1,051
– – ﹤0.01% 3011
2026
Q1 		$780 Hold
1,051
– – ﹤0.01% 2746
2025
Q4 		$1.36K Hold
1,051
– – ﹤0.01% 2529
2025
Q3 		$769 Hold
1,051
– – ﹤0.01% 2799
2025
Q2 		$758 Buy
+1,051
New +$1.15K ﹤0.01% 2795

Other funds holding KTTA

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities's KTTA Position: Q2 2026 in Review

SBI Securities held its Pasithea Therapeutics (KTTA) position steady in Q2 2026 at 1,051 shares worth $542. The position accounts for ﹤0.01% of the portfolio, ranked #3011.

SBI Securities first reported a position in KTTA in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.36K in Q4 2025. 13 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • SBI Securities held 1,051 shares of Pasithea Therapeutics worth $542 as of Q2 2026.
  • SBI Securities left its Pasithea Therapeutics share count unchanged in Q2 2026.
  • Pasithea Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3011 holding.
  • SBI Securities first reported a position in Pasithea Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • SBI Securities's Pasithea Therapeutics position peaked at $1.36K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.